Lactiga Continues to Build a Substantial Global Biologics Patent Portfolio
PRINCETON, N.J., July 20, 2021 (GLOBE NEWSWIRE) -- Lactiga, Inc. (Lactiga), a biotherapeutics company advancing anti-infective biologics to prevent mucosal infections in immunodeficient patients, announced today that the following patents have issued or received notices of allowance in June:
- PRINCETON, N.J., July 20, 2021 (GLOBE NEWSWIRE) -- Lactiga, Inc. (Lactiga), a biotherapeutics company advancing anti-infective biologics to prevent mucosal infections in immunodeficient patients, announced today that the following patents have issued or received notices of allowance in June:
US patent application no. - Tom Paschall, CEO of Checkmate Capital Group, added: "We congratulate the Lactiga team on reaching this important milestone in their patent strategy.
- DLA Piper represented Lactiga in the successful prosecution of these patent applications and other related applications.
- Lactiga is an award-winning, venture-backed biotherapeutics company developing novel biologics to treat and prevent infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases.